Dupuytren’s disease (DD) is a common chronic hand condition that affects patients worldwide. Presenting with palpable fibrotic nodules, the disease leads to progressive and irreversible flexion of digits, affecting patients’ hand function, impairing daily activities and potentially reducing the quality of life. Management techniques are primarily corrective and do not address the biological mechanisms underlying disease pathogenesis and progression. While non-surgical interventions are used to manage early stage DD, advanced disease requires surgical correction. This review provides an overview of the epidemiology and risk factors associated with DD and the latest research on the mechanisms underlying its progression. It summarizes the main non-surgical and surgical corrective options currently available and discusses the future of early stage DD treatment.
ÅgrenRPatilSZhouX, et al. Major genetic risk factors for Dupuytren’s disease are inherited from Neandertals. Mol Biol Evol. 2023, 40: msad130.
2.
AkhavaniMAMcMurtrieAWebbMMuirL. A review of the classification of Dupuytren’s disease. J Hand Surg Eur. 2015, 40: 155–65.
3.
AlserOCraigRSLaneJCE, et al. Serious complications and risk of re-operation after Dupuytren’s disease surgery: a population-based cohort study of 121,488 patients in England. Sci Rep. 2020a, 10: 16520.
4.
AlserOKuoRYLFurnissD. Nongenetic factors associated with Dupuytren’s disease: a systematic review. Plast Reconstr Surg. 2020b, 146: 799–807.
5.
AnthonySGLozano-CalderonSASimmonsBPJupiterJB. Gender ratio of Dupuytren’s disease in the modern U.S. population. Hand (NY). 2008, 3: 87–90.
6.
ArafaMNobleJRoyleSGTrailIAAllenJ.Dupuytren’s and epilepsy revisited. J Hand Surg Br. 1992, 17: 221–4.
7.
ArmstrongJRHurrenJSLoganAM.Dermofasciectomy in the management of Dupuytren’s disease. J Bone Joint Surg Br. 2000, 82: 90–4.
8.
AugoffKRatajczakKGoskJTabolaRRutowskiR.Gelatinase A activity in Dupuytren’s disease. J Hand Surg. 2006, 31: 1635–9.
9.
BallCIzadiDVerjeeLSChanJNanchahalJ.Systematic review of non-surgical treatments for early Dupuytren’s disease. BMC Musculoskelet Disord. 2016, 17: 345.
10.
BayatAMcGroutherDA.Management of Dupuytren’s disease – clear advice for an elusive condition. Ann R Coll Surg Engl. 2006, 88: 3–8.
11.
BoltAMGieleHMcNabISHSpiteriM. Outcome of arthrodesis for severe recurrent proximal interphalangeal joint contractures in Dupuytren’s disease. J Hand Surg Eur. 2021, 46: 403–5.
12.
BroekstraDCGroenHMolenkampSWerkerPMNvan den HeuvelER.A systematic review and meta-analysis on the strength and consistency of the associations between Dupuytren disease and diabetes mellitus, liver disease, and epilepsy. Plast Reconstr Surg. 2018, 141: 367e–79e.
13.
BroekstraDCLantingRWerkerPMNVan Den HeuvelER.Disease course of primary Dupuytren Ddisease: 5-year results of a prospective cohort study. Plast Reconstr Surg. 2022, 149: 1371–8.
BurgessTWegenerEMcClellandBHunter-SmithDWerkerPMNMartinJ. Adverse events after adjuvant radiation therapy for Dupuytren’s disease in the DEPART randomized trial. J Hand Surg Eur. 2025, 50: 891–7.
16.
CapstickRBraggTGieleHFurnissD. Sibling recurrence risk in Dupuytren’s disease. J Hand Surg Eur. 2013, 38: 424–9.
17.
DahlinLBBainbridgeCSzczypaPPCappelleriJCGuérinDGerberRA.Current trends in the surgical management of Dupuytren’s disease in Europe: the surgeon’s perspective. Eur Orthop Traumatol. 2012, 3: 25–30.
18.
DavisT.Hand-2: needle fasciotomy versus limited fasciectomy for the treatment of Dupuytren’s contractures of the fingers: a randomised, multi-centre non-inferiority trial. 2024. https://www.isrctn.com/ISRCTN12525655 (accessed 23 May 2024).
19.
DavisTTanWHarrisonEF, et al. A randomised feasibility trial comparing needle fasciotomy with limited fasciectomy treatment for Dupuytren’s contractures. Pilot Feasibility Stud. 2020, 6: 7.
20.
DegreefIDe SmetL.Dupuytren’s disease: a predominant reason for elective finger amputation in adults. Acta Chir Belg. 2009, 109: 494–7.
21.
DenklerKAParkKMAlserO.Treatment options for Dupuytren’s disease: tips and tricks. Plast Reconstr Surg Glob Open. 2022, 10: E4046.
22.
DescathaACartonMMediouniZ, et al. Association among work exposure, alcohol intake, smoking and Dupuytren’s disease in a large cohort study (GAZEL). BMJ Open. 2014, 4: 4214.
23.
DiasJJBraybrookeJ.Dupuytren’s contracture: an audit of the outcomes of surgery. J Hand Surg. 2006, 31: 514–21.
24.
DobieRWestCCHendersonBEP, et al. Deciphering mesenchymal drivers of human Dupuytren’s disease at single-cell level. J Invest Dermatol. 2022, 142: 114–23.e8.
25.
DolmansGHDe BockGHWerkerPM.Dupuytren diathesis and genetic risk. J Hand Surg Am. 2012, 37: 2106–11.
26.
DolmansGHWerkerPMHenniesHC, et al. Wnt signaling and Dupuytren’s disease. N Engl J Med. 2011, 365: 307–17.
27.
D’UrsoMKurniawanNA.Mechanical and physical regulation of fibroblast–myofibroblast transition: from cellular mechanoresponse to tissue pathology. Front Bioeng Biotechnol. 2020, 8: 609653.
28.
EiriksdottirAAtroshiI.A new finger-preserving procedure as an alternative to amputation in recurrent severe Dupuytren contracture of the small finger. BMC Musculoskelet Disord. 2019, 20: 323.
29.
FinsenVDalenHNesheimJ.The prevalence of Dupuytren’s disease among 2 different ethnic groups in northern Norway. J Hand Surg. 2002, 27: 115–7.
30.
GodtfredsenNSLuchtHPrescottESørensenTIAGrønbækM.A prospective study linked both alcohol and tobacco to Dupuytren’s disease. J Clin Epidemiol. 2004, 57: 858–63.
31.
GokelJMHuebnerG.Occurrence of myofibroblasts in the different phases of morbus Dupuytren (Dupuytren’s contracture). Beitr Pathol. 1977, 161: 166–75.
32.
GudmundssonKGArngrímssonRJónssonT.Eighteen years follow-up study of the clinical manifestations and progression of Dupuytren’s disease. Scand J Rheumatol. 2001, 30: 31–4.
33.
GudmundssonKGArngrimssonRSigfussonNBjornssonAJonssonT.Epidemiology of Dupuytren’s disease: clinical, serological, and social assessment. The Reykjavik Study. J Clin Epidemiol. 2000, 53: 291–6.
34.
HacquebordJHChiuVYHarnessNG.The risk of Dupuytren surgery in obese Individuals. J Hand Surg. 2017, 42: 149–55.
35.
HindochaSMcGroutherDABayatA.Epidemiological evaluation of Dupuytren’s disease incidence and prevalence rates in relation to etiology. Hand (NY). 2009, 4: 256–69.
36.
HindochaSStanleyJKWatsonSBayatA.Dupuytren’s diathesis revisited: evaluation of prognostic indicators for risk of disease recurrence. J Hand Surg. 2006, 31: 1626–34.
37.
HindochaSStanleyJKWatsonJSBayatA.Revised Tubiana’s staging system for assessment of disease severity in Dupuytren’s disease – preliminary clinical findings. Hand. 2008, 3: 80–6.
38.
HoviusSERKanHJVerhoekxJSNKhouriRK. Percutaneous aponeurotomy and lipofilling (PALF): a regenerative approach to Dupuytren contracture. Clin Plast Surg. 2015, 42: 375–81.
39.
HuFZNystromAAhmedA, et al. Mapping of an autosomal dominant gene for Dupuytren’s contracture to chromosome 16q in a Swedish family. Clin Genet. 2005, 68: 424–9.
40.
HuestonJTMcFarlaneR. The Dupuytren’s diathesis. In: HuestonJT (Ed.) Dupuytren’s contracture. Edinburgh, E & S Livingstone, 1963: 51–63.
41.
HuestonJT.Regression of Dupuytren’s contracture. J Hand Surg Br. 1992, 17: 453–7.
42.
IqbalSAManningCSyedF, et al. Identification of mesenchymal stem cells in perinodular fat and skin in Dupuytren’s disease: a potential source of myofibroblasts with implications for pathogenesis and therapy. Stem Cells Dev. 2012, 21: 609–22.
43.
ItohYNgMWibergA, et al. A common SNP risk variant MT1-MMP causative for Dupuytren’s disease has a specific defect in collagenolytic activity. Matrix Biology. 2021, 97: 20–39.
44.
KanHJSellesRWVan NieuwenhovenCAZhouCKhouriRKHoviusSER. Percutaneous aponeurotomy and lipofilling (PALF) versus limited fasciectomy in patients with primary Dupuytren’s contracture: a prospective, randomized, controlled trial. Plast Reconstr Surg. 2016, 137: 1800–12.
KarkampounaSKreulenMObdeijnMC, et al. Connective tissue degeneration: mechanisms of palmar fascia degeneration (Dupuytren’s disease). Curr Mol Biol Rep. 2016, 2: 133–40.
47.
KendallRTFeghali-BostwickCA.Fibroblasts in fibrosis: novel roles and mediators. Front Pharmacol. 2014, 5: 123.
48.
KuoRYLNgMPrieto-AlhambraDFurnissD. Dupuytren’s disease predicts increased all-cause and cancer-specific mortality: analysis of a large cohort from the U.K. Clinical Practice Research Datalink. Plast Reconstr Surg. 2020, 145: 574E–82E.
49.
LamWLRawlinsJMKarooROSNaylorISharpeDT.Re-visiting Luck’s classification: a histological analysis of Dupuytren’s disease. J Hand Surg Am. 2010, 35: 312–7.
50.
LambiAGMorrellNTPopoffSNBenhaimPBarbeMF.Let’s focus on the fibrosis in Dupuytren disease: cell communication network factor 2 as a novel target. J Hand Surg Glob Online. 2023, 5: 682–8.
51.
LantingRVan Den HeuvelERWesterinkBWerkerPMN. Prevalence of Dupuytren disease in the Netherlands. Plast Reconstr Surg. 2013, 132: 394–403.
52.
LarsenSKrogsgaardDGLarsenLAIachinaMSkyttheAFrederiksenH. Genetic and environmental influences in Dupuytren’s disease: a study of 30,330 Danish twin pairs. J Hand Surg Eur. 2015, 40: 171–6.
53.
LaytonTBWilliamsLMcCannF, et al. Cellular census of human fibrosis defines functionally distinct stromal cell types and states. Nat Commun. 2020, 11: 2768.
54.
LaytonTBWilliamsLYangN, et al. A vasculature niche orchestrates stromal cell phenotype through PDGF signalling: importance in human fibrotic disease. Proc Natl Acad Sci USA. 2022, 119: e2120336119.
55.
LuckVJ.Dupuytren’s contracture: a new concept of the pathogenesis correlated with surgical management. J Bone Joint Surg. 1959, 41: 635–64.
56.
MansurHGde OliveiraERGonçalvesCB.Epidemiological analysis of patients with Dupuytren’s disease. Rev Bras Ortop. 2018, 53: 10–14.
57.
MartinJMBurgessTMcClellandB, et al. Toxicities and quality of life following observation or radiation therapy for Dupuytren’s disease: three-year secondary analysis data from the prevention group of the international Dupuytren’s evaluation of preventative or adjuvant radiation therapy (DEPART) randomized trial. Int J Radiat Oncol Biol Phys. 2026; 124: 604–13.
58.
MendelaarNHAPoelstraRVan NieuwenhovenCA, et al. Outcome of recurrent surgery in Dupuytren’s disease: comparison with initial treatment. Plast Reconstr Surg. 2019, 144: 828E–35E.
59.
MorelliIFraschiniGBanfiAE.Dupuytren’s disease: predicting factors and associated conditions. A single center questionnaire-based case-control study. Arch Bone Jt Surg. 2017, 5: 384.
60.
NanchahalJChanJK-K. Treatments for early-stage Dupuytren’s disease: an evidence-based approach. J Hand Surg Eur. 2023, 48: 191–8.
61.
NanchahalJBallCRombachI, et al. Anti-tumour necrosis factor therapy for early-stage Dupuytren’s disease (RIDD): a phase 2b, randomised, double-blind, placebo-controlled trial. Lancet Rheumatol. 2022, 4: e407–16.
62.
NgMThakkarDSouthamL, et al. A genome-wide association study of Dupuytren disease reveals 17 additional variants implicated in fibrosis. Am J Hum Genet. 2017, 101: 417–27.
63.
NovoJGaoDSethIRozenWM. Incidence of Dupuytren’s disease following hand trauma: a systematic review. J Hand Surg Eur. 2026, 51: 6–13.
64.
OnNKohSPBraschHD, et al. Embryonic stem cell-like population in Dupuytren’s disease expresses components of the renin-angiotensin system. Plast Reconstr Surg Glob Open. 2017, 5: e1422.
65.
PalmerKTD’AngeloSSyddallHGriffinMJCooperCCoggonD.Dupuytren’s contracture and occupational exposure to hand-transmitted vibration. Occup Environ Med. 2014, 71: 241–5.
RiesmeijerSAKamaliZNgM, et al. A genome-wide association meta-analysis implicates hedgehog and notch signaling in Dupuytren’s disease. Nat Commun. 2024, 15: 199.
68.
RodriguesJNBeckerGWBallC, et al. Surgery for Dupuytren’s contracture of the fingers. Cochrane Database Syst Rev. 2015, 2015: CD010143.
69.
SalariNHeydariMHassanabadiM, et al. The worldwide prevalence of the Dupuytren disease: a comprehensive systematic review and meta-analysis. J Orthop Surg Res. 2020, 15: 495.
70.
SandersonPLMorrisMAStanleyJKFahmyNRM. Lipids and Dupuytren’s disease. J Bone Joint Surg Br. 1992, 74: 923–7.
71.
SellesRWZhouCKanHJWoutersRMVan NieuwenhovenCAHoviusSER. Percutaneous aponeurotomy and lipofilling versus limited fasciectomy for Dupuytren’s contracture: 5-year results from a randomized clinical trial. Plast Reconstr Surg. 2018, 142: 1523–31.
ShihBWatsonSBayatA.Whole genome and global expression profiling of Dupuytren’s disease: systematic review of current findings and future perspectives. Ann Rheum Dis. 2012, 71: 1440–7.
74.
TherkelsenLHSkovSTLaursenMLangeJ.Percutaneous needle fasciotomy in Dupuytren contracture: a register-based, observational cohort study on complications in 3,331 treated fingers in 2,257 patients. Acta Orthop. 2020, 91: 326–30.
75.
UllahASDiasJJBhowalB.Does a ‘firebreak’ full-thickness skin graft prevent recurrence after surgery for Dupuytren’s contracture? A prospective, randomised trial. J Bone Joint Surg Br. 2009, 91: 374–8.
76.
Van Den BergeBAGroenhofFWerkerPMN, et al. Mortality in patients with Dupuytren’s disease in the first 5 years after diagnosis: a population-based survival analysis. J Hand Surg Eur. 2024, 49: 1110–8.
77.
Van Den BergeBAWerkerPMNBroekstraDC. Limited progression of subclinical Dupuytren’s disease results from a prospective cohort study. Bone Joint J. 2021, 103-B: 704–10.
78.
Van Den BergeBAWibergAWerkerPMNBroekstraDCFurnissD.Dupuytren’s disease is a work-related disorder: results of a population-based cohort study. Occup Environ Med. 2023, 80: 137.
79.
Van RijssenALTer LindenHWerkerPMN.Five-year results of a randomized clinical trial on treatment in Dupuytren’s disease: percutaneous needle fasciotomy versus limited fasciectomy. Plast Reconstr Surg. 2012, 129: 469–77.
80.
Van StraalenRJMBroekstraDCWerkerPMNDe BoerMR.The presentation and treatment of Dupuytren’s disease in Dutch general practitioner care. Fam Pract. 2025, 42: cmae065.
81.
VerhoekxJSNMuderaVWalbeehmETHoviusSER. Adipose-derived stem cells inhibit the contractile myofibroblast in Dupuytren’s disease. Plast Reconstr Surg. 2013, 132: 1139–48.
82.
VerjeeLSVerhoekxJSNChanJKK, et al. Unraveling the signaling pathways promoting fibrosis in Dupuytren’s disease reveals TNF as a therapeutic target. Proc Natl Acad Sci USA. 2013, 110: E928–37.
83.
WalthallJAnandPRehmanUH. Dupuytren contracture. In: FronteraWRSilverJKRizzoTDJr (Eds.) Essentials of physical medicine and rehabilitation: musculoskeletal disorders, pain, and rehabilitation. 4th ed.Philadelphia, Elsevier, 2019: 154–58.
84.
WangZWangZYanZXuZGaoA.Smoking, alcohol consumption and risk of Dupuytren’s disease: a Mendelian randomization study. BMC Med Genomics. 2023, 16: 1–8.
85.
WilburnJMckennaSPPerry-HinsleyDBayatA.The impact of Dupuytren disease on patient activity and quality of life. J Hand Surg. 2013, 38: 1209–14.
86.
YuanSFurnissDLarssonSCLefflerDALudvigssonJF.Celiac disease and incident Dupuytren’s contracture: a matched nationwide cohort analysis. Clin Epidemiol. 2025, 17: 481–4.
